Business Wire

Servier and Taiho Announce Phase III Trial Data Demonstrates Significant Overall Survival Benefit of LONSURF® (trifluridine and tipiracil) in Patients with Metastatic Gastric Cancer

Del

Servier and Taiho Pharmaceutical Co., Ltd. today announced clinical data from the pivotal Phase III trial (TAGS) for LONSURF® (trifluridine and tipiracil, TAS-102) which showed significant improvement in overall survival (OS) for the treatment of patients with refractory metastatic gastric cancer (HR=0.69 [95% IC 0.56-0.85], p=0.0003). The median overall survival in patients treated with trifluridine/tipiracil and best supportive care (BSC) was 5.7 months as compared to 3.6 months when treated with placebo and BSC, and they had a 31% risk reduction of death. At 12-months, OS rates were 21.2% in the trifluridine/tipiracil group and 13.0% in the placebo group. In addition, the risk for disease progression measured by PFS, a key secondary endpoint, was reduced by 43% (HR: 0.57).

The overall safety profile was consistent with the known safety profile of trifluridine/tipiracil in metastatic colorectal cancer (CRC), with mainly hematological adverse events reported.

“The results presented today from TAGS demonstrate the potential of trifluridine/tipiracil in this group of patients with late-stage metastatic gastric cancer”, said Professor Josep Tabernero. Head of the Medical Oncology Department, Vall d’Hebron University Hospital, Barcelona and Director of the Vall d’Hebron Institute of Oncology (VHIO). “Patients at this stage of the disease have very few remaining therapeutic options and it is important that efficacious and manageable treatments are available to expand patient’s survival.”

Ali Zeaiter, Head of Servier Oncology Clinical Development Department added, “We are pleased that trifluridine/tipiracil has shown significant benefit for patients with metastatic gastric cancer who are in need of effective treatments when there are few options remaining. We are committed to improving patients’ outcomes and to providing access to new therapeutic options. We will continue to collaborate with regulatory bodies to progress our mission to make trifluridine/tipiracil accessible to patients and medical professionals.”

Trifluridine/tipiracil is currently indicated in Europe for the treatment of adult patients with metastatic CRC who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.1

About TAGS

TAGS ( TA S-102 G astric S tudy) is a Taiho-sponsored pivotal Phase III multinational, randomized, double-blind study evaluating trifluridine and tipiracil, plus best supportive care (BSC) versus placebo plus BSC in patients with metastatic gastric cancer refractory to standard treatments. The primary endpoint in TAGS is overall survival (OS), and secondary endpoint measures include progression-free survival (PFS), safety and tolerability, as well as quality of life.

TAGS enrolled 507 adult patients with metastatic gastric cancer who had previously received at least two prior regimens for advanced disease. The trial was conducted in Europe, Russia, Turkey, Japan, and North America.

For more information on TAGS, please visit www.ClinicalTrials.gov (https://clinicaltrials.gov/ct2/show/NCT02500043 ). The ClinicalTrials.gov Identifier is NCT02500043.

About Metastatic Gastric Cancer

Gastric cancer, also known as stomach cancer, is a disease in which malignant cells form in the lining of the stomach. It is the fifth most common cancer worldwide and the third most common cause of cancer-related death (after lung and liver cancer), with an estimated 723,000 deaths annually.2 Approximately 50 percent of patients with gastric cancer have advanced disease at the time of diagnosis.3

Standard chemotherapy regimens for advanced gastric cancer include fluoropyrimidines, platinum derivatives, and taxanes, or irinotecan. The addition of trastuzumab to chemotherapy is standard of care for patients with HER2-neu-positive advanced gastric cancer. However, after failure of first- and second-line therapies, standard third line treatments are limited.

About LONSURF ® (trifluridine and tipiracil, TAS-102)

LONSURF® is an oral anticancer drug, comprising a combination of trifluridine (FTD) and tipiracil (TPI), whose dual mechanism of action is designed to maintain clinical activity. LONSURF® is registered in Japan, USA, European Union and in many other countries. In the European Union, LONSURF® is indicated for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan- based chemotherapies, anti-VEGF agents, and anti-EGFR agents.i

LONSURF® is recommended by the National Institute for Health and Care Excellence (NICE),4 NCCN5,6 and ESMO Guidelines7 for the treatment of adult patients with metastatic colorectal cancer.

In June 2015, Servier and Taiho Pharmaceutical entered into an exclusive license agreement for the co-development and commercialization of LONSUF®.

About Servier

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 148 countries and a turnover of 4.152 billion euros in 2017, Servier employs 21,600 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.

Becoming a key player in oncology is part of Servier’s long-term strategy. Currently, there are nine molecular entities in clinical development in this area, targeting gastric and lung cancers and other solid tumors, as well as different types of leukemia and lymphomas. This portfolio of innovative cancer treatments is being developed with partners worldwide, and covers different cancer hallmarks and modalities, including cytotoxics, proapoptotics, immune, cellular and targeted therapies, to deliver life-changing medicines to patients.

More information: www.servier.com

Find us on Social Media:

LinkedIn
Facebook
Twitter

About Taiho Pharmaceutical Co., Ltd. (Japan)

Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd. (https://www.otsuka.com/en/), is an R&D-driven specialty pharma focusing on the three fields of oncology, allergy and immunology, and urology. Its corporate philosophy takes the form of a pledge: “We strive to improve human health and contribute to a society enriched by smiles.” In the field of oncology, in particular, Taiho Pharmaceutical is known as a leading company in Japan for developing innovative medicines for the treatment of cancer, a reputation that is rapidly expanding through their extensive global R&D efforts. In areas other than oncology, as well, the company creates and markets quality products that effectively treat medical conditions and can help improve people's quality of life. Always putting customers first, Taiho Pharmaceutical also aims to offer consumer healthcare products that support people's efforts to lead fulfilling and rewarding lives.

For more information about Taiho Pharmaceutical, please visit: https://www.taiho.co.jp/en/.

1 European Medicines Agency. Lonsurf. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003897/human_med_001975.jsp&mid=WC0b01ac058001d124 Last accessed May 2018.
2 Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr
3 National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Gastric cancer. V.1.2018.
4 NICE TA405. Available at: www.nice.org.uk/guidance/TA405 Last accessed May 2018.
5 National Comprehensive Cancer Network (NCCN). NCCN Guidelines Insights: Colon Cancer, Version 2.2018.
6 National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Patients: Rectal Cancer, Version 1.2017.
7 ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: Van Cutsem E et al. Ann Oncol. 2016;27:1386-422.

Contact information

Servier
Sonia MARQUES
media@servier.com
Tél. +33 (0)1 55 72 40 21 / + 33 (0) 7 84 28 76 13
or
Karine BOUSSEAU
media@servier.com
Tél. +33 (0)1 55 72 60 37

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

New Guidance From ADA and EASD Recommends Use of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Patients with Type 2 Diabetes16.10.2018 13:15Pressemelding

As the European distributor of INVOKANA ® (canagliflozin) and VOKANAMET ® (canagliflozin and metformin) Mundipharma welcomes the news that SGLT2i’s, including canagliflozin, have now been included as an important treatment option in the newly published 2018 ADA/EASD Consensus Report in the early management of T2DM patients with established ASCVD, HF, CKD and also in patients without cardiovascular disease (CVD) especially where there is a compelling need to minimize weight gain or promote weight loss or a need to minimize the risk of hypoglycaemia. The new guidance was co-published in Diabetologia, the journal of EASD, and Diabetes Care, the journal of the ADA, during the annual meeting of EASD in Berlin, Germany on October 5.1 Updates to the guidance took into consideration recent evidence from large CV outcome trials (CVOTs), which included the CANVAS programme, the largest completed and published CV outcomes trial to date for an SGLT2i, which has shown that canagliflozin reduces the

Brightree Launches First Patient App for HME16.10.2018 13:05Pressemelding

Brightree®, the leading provider of cloud-based software to help post-acute care companies improve business performance and patient outcomes, announced today from Medtrade the release of its new Patient Hub to personalize the patient experience and increase revenue for home medical equipment (HME) providers. Patient Hub is a patient engagement app that automates and simplifies how HME providers connect with their patients. It eliminates the need for multiple web portals and consolidates all patient interactions into one secure platform. By improving ease of engagement and automation, Patient Hub empowers care, frees up resources and creates opportunities to accelerate cash flow. The Patient Hub app allows providers to automate simple, repetitive processes such as sending out appointment reminders and requests for insurance updates, or delivering order status and tracking updates. Patients can initiate and complete tasks as well, including updating account information, reordering suppli

KYMCO Announces Entry Into India With Ionex16.10.2018 12:40Pressemelding

KYMCO announces its official entry into India with its game-changing Ionex electric scooter total solution. In partnership with Twenty Two Motors, an Indian company that focuses on developing advanced connected electric vehicles, KYMCO is set to revolutionize the two-wheeler sector in India by bringing the new era of electric scooters and building the open energy platforms long awaited by Indian customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181016005636/en/ Allen Ko, Chairman, KYMCO (Photo: Business Wire) India is the largest two-wheeler market in the world. The Indian government is actively promoting green movement through policies that encourage the use of electric vehicles as well as the establishment of EV infrastructure. The latest ‘National E-Mobility Programme’ aims to shift one third of petrol and diesel vehicles to electric by 2030. The government has a strong motivation for “go electric, go green” revol

AGCO Chairman, President and Chief Executive Officer Martin Richenhagen Receives the French Government's Prestigious Legion of Honor16.10.2018 12:00Pressemelding

AGCO (NYSE: AGCO), a global leader in the design, manufacture and distribution of agricultural machinery and solutions, today announces that Martin Richenhagen, Chairman, President and Chief Executive Officer of AGCO Corporation, has been named a Chevalier (Knight) of the Légion d'Honneur (Legion of Honor) by the government of France. This high-ranking honorary decoration was bestowed during a recent ceremony held at AGCO’s global headquarters in Duluth, in the presence of the French Consul General in Atlanta, Louis de Corail. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181016005270/en/ Martin Richenhagen, Chairman, President and Chief Executive Officer of AGCO Corporation, has been named a Chevalier (Knight) of the Légion d'Honneur (Legion of Honor) by the government of France during a recent ceremony in Duluth, Georgia, USA. (Photo: Business Wire) The Legion of Honor, established by Napoléon Bonaparte in 1802, is the hi

Fujitsu to Demonstrate New “Super-Slim” Washable RFID Linen Tags at the EXPOdetergo 18th International Exhibition in Milan, Italy16.10.2018 12:00Pressemelding

Fujitsu Frontech North America Inc., a leader in innovative technology and front-end solutions, has announced today that Fujitsu has developed a new line of washable UHF RFID tags only 7 millimeters wide, 30% smaller than current tags, allowing them to be more easily inserted into the seams of washable items. Fujitsu will debut the new “super-slim” tags, as well as their WT-A533 Linen tags and WT-A533L Fashion tags, at the EXPOdetergo 18th International Exhibition, Hall 1 booth # V10, on October 19-22, 2018, at the Fiera Milano Convention Center, Milan, Italy. The Fujitsu “super-slim” washable RFID Linen tags are targeted for availability in the first quarter of 2019. “Fujitsu has been creating RFID solutions for over 20 years. Our engineering and design teams possess sophisticated engineering, design and antenna optimization intellectual property,” says Michi Sugawara, President and CEO of Fujitsu Frontech North America Inc. “By combining this know-how plus our skills in high-volume,

Quotient Sciences Constructs State-of-the-Art Early-Phase Formulation and Manufacturing Facility in U.S.16.10.2018 12:00Pressemelding

Quotient Sciences, a leading drug development services organization, announces a significant expansion to its operations in the U.S. with the opening of a state-of-the-art, 45,000-square-foot facility located near Philadelphia, in Garnet Valley, Pa. The $15 million investment will create a center of excellence for early-phase formulation development and clinical trial manufacturing. The Garnet Valley site will focus on developing small molecule oral drug products, supporting development programs from the preclinical stage through to clinical proof-of-concept. Seamless scale-up to late-phase manufacturing and commercial product supply will continue at Quotient’s nearby Chelsea Parkway facility. “Our new facility was built in response to increasing customer demand for our early-phase formulation development and clinical trial manufacturing services,” said Mark Egerton, Ph.D., CEO of Quotient Sciences. “The site was specifically designed to optimize our ability to work with highly potent